IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone212-845-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$209.98 million
Profitability
Miscellaneous
Employees35
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions
What is IVERIC bio's stock symbol?
IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."
How were IVERIC bio's earnings last quarter?
IVERIC bio Inc (NASDAQ:ISEE) issued its earnings results on Thursday, August, 1st. The company reported ($0.35) earnings per share for the quarter. View IVERIC bio's Earnings History.
When is IVERIC bio's next earnings date?
What price target have analysts set for ISEE?
1 Wall Street analysts have issued 1 year price objectives for IVERIC bio's shares. Their forecasts range from $1.25 to $1.25. On average, they expect IVERIC bio's share price to reach $1.25 in the next year. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Price Targets for IVERIC bio.
What is the consensus analysts' recommendation for IVERIC bio?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for IVERIC bio.
Has IVERIC bio been receiving favorable news coverage?
Media coverage about ISEE stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IVERIC bio earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for IVERIC bio.
Who are some of IVERIC bio's key competitors?
Some companies that are related to IVERIC bio include Nature's Sunshine Products (NATR), Acasti Pharma (ACST), Imprimis Pharmaceuticals (IMMY), Bicycle Therapeutics (BCYC), Arcturus Therapeutics (ARCT), Hookipa Pharma (HOOK), Axovant Gene Therapies (AXGT), Generex Biotechnology (GNBT), REDHILL BIOPHAR/S (RDHL), Applied Therapeutics (APLT), Mustang Bio (MBIO), Newron Pharmaceuticals (NWPHF), Sol Gel Technologies (SLGL), Abeona Therapeutics (ABEO) and TAIWAN LIPOSOME/S (TLC).
Who are IVERIC bio's key executives?
IVERIC bio's management team includes the folowing people:
- Dr. David R. Guyer, Exec. Chairman (Age 59)
- Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)
- Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)
- Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)
- Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44)
Who are IVERIC bio's major shareholders?
IVERIC bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.90%), Tamarack Advisers LP (7.22%), Acadian Asset Management LLC (3.03%), Renaissance Technologies LLC (2.97%), Vanguard Group Inc. (2.73%) and Connor Clark & Lunn Investment Management Ltd. (2.09%). Company insiders that own IVERIC bio stock include David Francis Carroll and Glenn Sblendorio. View Institutional Ownership Trends for IVERIC bio.
Which major investors are buying IVERIC bio stock?
ISEE stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Tamarack Advisers LP, Acadian Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., Morgan Stanley and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for IVERIC bio.
How do I buy shares of IVERIC bio?
Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IVERIC bio's stock price today?
One share of ISEE stock can currently be purchased for approximately $1.13.
How big of a company is IVERIC bio?
IVERIC bio has a market capitalization of $46.96 million and generates $209.98 million in revenue each year. The company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. IVERIC bio employs 35 workers across the globe.View Additional Information About IVERIC bio.
What is IVERIC bio's official website?
How can I contact IVERIC bio?
IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected]
MarketBeat Community Rating for IVERIC bio (NASDAQ ISEE)
MarketBeat's community ratings are surveys of what our community members think about IVERIC bio and other stocks. Vote "Outperform" if you believe ISEE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISEE will underperform the S&P 500 over the long term. You may vote once every thirty days.
